VKTX
Viking Therapeutics, Inc.
17.48
USD
This page is just a preview of the data found in TrendSpider’s full version
Viking Therapeutics, Inc. stock is up 67.92% since 30 days ago. The next earnings date is Feb 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 8 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 05 Dec 15:17 | 17 May, 2024 | 19.00 | 24 | ||
| 05 Dec 17:36 | 19 Jan, 2024 | 10.00 | 1851 | ||
| 05 Dec 18:43 | 17 May, 2024 | 19.00 | 24 | ||
| 05 Dec 18:50 | 17 May, 2024 | 19.00 | 24 | ||
| 05 Dec 20:29 | 19 Jan, 2024 | 15.00 | 4445 | ||
| 05 Dec 20:42 | 19 Jan, 2024 | 15.00 | 4445 | ||
| 06 Dec 14:33 | 17 May, 2024 | 14.00 | 188 | ||
| 06 Dec 14:44 | 19 Jan, 2024 | 17.00 | 2989 | ||
| 06 Dec 14:53 | 19 Jan, 2024 | 20.00 | 2420 | ||
| 06 Dec 17:21 | 17 May, 2024 | 20.00 | 393 |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
